Theralase Technologies Inc. V.TLT

From Roche

[langosta]

https://health.economictimes.indiatimes.com/news/pharma/new-cancer-immunotherapy-fails-in-first-roche-trial/90542083

[blackjack0]

I feel This failure by Roche has positive implications for our trials. The bar is not very high 

[ScienceFirst]

In the article posted by Langosta, we can also see some valuation deals for one immunotherapy adjuvant.  Not only does it have to be used in combo, it also failed! So name your tag price if we destroy, alone, with no assistance, no side effects, in 2 treatments! In a statement on Wednesday, the company said the drug, when combined with its established cancer drug Tecentriq and

[ScienceFirst]

And this anti-TIGIT technology has been granted Breakthrough designation. Based on what you see below, don't worry about our Breakthrough designation.  It's coming for sure.  We just need to see the next round of data to officially confirm this.  Just to be on the safe side. Dec. 10, 2021: New data from the phase II CITYSCAPE trial show encouraging results with Roche’s